There could be a downside, she said
Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD)
Overall Clinical Fit: "More weight loss on average" does not automatically mean "best choice for every patient." Your doctor will consider medication tolerability, insurance coverage, existing comorbidities, and your personal medical history when deciding between the two
There is, however, a class of medications known as GLP-1 agonists, which a medical professional may consider in the treatment of diagnosable diseases such as Type 2 diabetes
Chi-Square (or Fisher's
What is the "PPI Trap" and how do I avoid it